Waystar Considers Sale Amid Market Volatility, Sources Reveal

Waystar, a prominent healthcare software firm, is reportedly exploring strategic alternatives, including a potential sale, according to insiders familiar with the situation. The development comes as the company's market value has decreased to approximately $4.8 billion, following a 24% decline in its share price this year amid a broader downturn in the software sector.

Waystar's Strategic Shift

Founded through the 2017 merger of Zirmed and Navicure, Waystar has positioned itself as a technology firm, offering software solutions to automate and manage administrative tasks in healthcare settings. This strategic positioning aimed to capitalize on the higher valuations typically associated with tech companies, as opposed to those that rely more on human resources for service delivery.

Despite an initial surge in investor interest, which saw Waystar's stock rise from $20 to a peak of $45 in 2025, the company's shares have faced pressure. Analysts from Morgan Stanley have noted investor concerns about potential disruptions from advancements in artificial intelligence.

Exploring Options with Evercore

Waystar has enlisted the services of investment bank Evercore to guide the exploration of its strategic options. Sources indicate that the process is in its early stages, and while a sale is among the possibilities, no definitive decisions have been made. The sources, who spoke on condition of anonymity due to the confidential nature of the discussions, cautioned that plans could change, and a sale may not ultimately occur.

The potential sale could return Waystar to private ownership just two years after its public listing on the New York Stock Exchange. The company's major shareholders include EQT, with a 13% stake, the Canada Pension Plan Investment Board holding 10%, and BlackRock Institutional Trust Company with 8%, according to data from LSEG.

Market Dynamics and Future Prospects

The healthcare software sector has been under scrutiny as investors reassess the landscape amid technological advancements and market fluctuations. The outcome of Waystar's exploratory process could signal broader trends in investor appetite for software firms, particularly those providing healthcare solutions.

Waystar's decision to explore these options highlights the challenges facing companies in maintaining market confidence and valuation in a rapidly evolving technological environment. The company's representatives, as well as those from EQT and BlackRock, declined to comment on the ongoing process, while CPPIB did not immediately respond to requests for comment.